Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic fat export refers to the biological process by which the liver removes excess lipids through the formation and secretion of very low-density lipoprotein (VLDL) particles into the bloodstream[1][2]. This process is essential for maintaining hepatic lipid homeostasis and preventing fat accumulation in the liver. The export mechanism involves key components including apolipoprotein B100 (apoB100) and microsomal triglyceride transfer protein (MTTP), which facilitate the assembly of VLDL particles in the endoplasmic reticulum[1][2]. These particles contain triglycerides, cholesterol, phospholipids, and apolipoproteins, and are subsequently transported to the Golgi apparatus where they mature before being secreted into circulation[2]. Impaired hepatic fat export is a critical factor in the development of fatty liver diseases, as it leads to hepatic lipid accumulation and steatosis[1][2]. In conditions like NAFLD and alcoholic fatty liver disease, the export capacity may initially increase as a compensatory mechanism but eventually plateaus or decreases with disease progression, contributing to further lipid accumulation and liver damage[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic fat export.